Technical Analysis for GMAB - Genmab A/S
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 20.45 | -0.24% | -0.05 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | -0.24% | |
NR7 | Range Contraction | -0.24% | |
NR7-2 | Range Contraction | -0.24% |
Alert | Time |
---|---|
Possible NR7 | about 18 hours ago |
Fell Below Previous Day's Low | about 22 hours ago |
New 52 Week Low | about 22 hours ago |
Rose Above Lower Bollinger Band | about 23 hours ago |
Possible NR7 | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 11/06/2024
Genmab A/S Description
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Classification
Sector: Healthcare
Industry: Long-Term Care Facilities
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunology Solid Tumors Drugs Antibodies Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Genetics Acute Myeloid Leukemia Lymphoma Parkinson's Disease Immunotherapies Non Small Cell Lung Cancer Multiple Sclerosis Multiple Myeloma Orphan Drug Breakthrough Therapy Amyloid Amyloidosis Antibody Drug Conjugate Chronic Lymphocytic Leukemia Lymphocytic Leukemia Advanced Cancer Camidanlumab Tesirine Cd20 Copenhagen Treatment Of Chronic Lymphocytic Leukemia Advanced Cancers Genmab
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 32.88 |
52 Week Low | 20.36 |
Average Volume | 1,180,064 |
200-Day Moving Average | 26.95 |
50-Day Moving Average | 23.40 |
20-Day Moving Average | 22.22 |
10-Day Moving Average | 21.69 |
Average True Range | 0.48 |
RSI (14) | 25.37 |
ADX | 42.33 |
+DI | 12.55 |
-DI | 45.13 |
Chandelier Exit (Long, 3 ATRs) | 22.03 |
Chandelier Exit (Short, 3 ATRs) | 21.80 |
Upper Bollinger Bands | 24.16 |
Lower Bollinger Band | 20.28 |
Percent B (%b) | 0.04 |
BandWidth | 17.44 |
MACD Line | -0.79 |
MACD Signal Line | -0.61 |
MACD Histogram | -0.1757 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 20.74 | ||||
Resistance 3 (R3) | 20.74 | 20.64 | 20.69 | ||
Resistance 2 (R2) | 20.64 | 20.57 | 20.64 | 20.67 | |
Resistance 1 (R1) | 20.55 | 20.53 | 20.50 | 20.55 | 20.66 |
Pivot Point | 20.45 | 20.45 | 20.43 | 20.45 | 20.45 |
Support 1 (S1) | 20.36 | 20.38 | 20.31 | 20.36 | 20.24 |
Support 2 (S2) | 20.26 | 20.34 | 20.26 | 20.23 | |
Support 3 (S3) | 20.17 | 20.26 | 20.21 | ||
Support 4 (S4) | 20.17 |